These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 39043756)

  • 1. Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy.
    Shi Z; Liu Y; Fang X; Liu X; Meng J; Zhang J
    Sci Rep; 2024 Jul; 14(1):16899. PubMed ID: 39043756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Shi Y; Lu H; Zhang Y
    Breast Cancer Res Treat; 2024 Jul; 206(2):387-395. PubMed ID: 38658447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis.
    Shao Y; Yu Y; Luo Z; Guan H; Zhu F; He Y; Chen Q; Liu C; Nie B; Liu H
    Ann Surg Oncol; 2022 Dec; 29(13):8026-8034. PubMed ID: 35933542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis.
    Li H; Plichta JK; Li K; Jin Y; Thomas SM; Ma F; Tang L; Wei Q; He YW; Chen Q; Guo Y; Liu Y; Zhang J; Luo S
    Breast Cancer Res Treat; 2024 Feb; 204(1):89-105. PubMed ID: 38066250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
    Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study.
    Özyurt N; Alkan A; Gülbağcı B; Seyyar M; Aydın E; Şahbazlar M; Türker M; Kınıkoğlu O; Yerlikaya T; Dinç G; Aytaç A; Kalkan Z; Ebinç S; Gültürk İ; Keskinkılıç M; İşleyen ZS; Çağlayan D; Türkel A; Aydın E; Şakalar T; Sekmek S; Yıldırım N; Koçak S; Okutur K; Özveren A; Dursun B; Kitaplı S; Eren OÖ; Beypınar İ; Hacıbekiroğlu İ; Çabuk D; Karaman E; Acar Ö; Paydaş S; Eryılmaz MK; Demir B; Oruç Z; Yılmaz M; Biricik FS; Salim DK; Tanrıverdi Ö; Doğan M
    Sci Rep; 2024 Oct; 14(1):23556. PubMed ID: 39384975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer.
    Yi X; Hu S; Ma M; Huang D; Zhang Y
    Clin Transl Oncol; 2024 Apr; 26(4):880-890. PubMed ID: 37702827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer.
    Narusawa E; Kurozumi S; Katayama A; Koibuchi Y; Ogawa A; Takata D; Tokuda S; Obayashi S; Oyama T; Horiguchi J; Shirabe K; Fujii T
    Med Mol Morphol; 2024 Sep; 57(3):177-184. PubMed ID: 38619618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
    Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
    Denkert C; Seither F; Schneeweiss A; Link T; Blohmer JU; Just M; Wimberger P; Forberger A; Tesch H; Jackisch C; Schmatloch S; Reinisch M; Solomayer EF; Schmitt WD; Hanusch C; Fasching PA; Lübbe K; Solbach C; Huober J; Rhiem K; Marmé F; Reimer T; Schmidt M; Sinn BV; Janni W; Stickeler E; Michel L; Stötzer O; Hahnen E; Furlanetto J; Seiler S; Nekljudova V; Untch M; Loibl S
    Lancet Oncol; 2021 Aug; 22(8):1151-1161. PubMed ID: 34252375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
    Qiao W; Guo W; Liu Q; Guo X; Deng M
    Ann Diagn Pathol; 2023 Jun; 64():152125. PubMed ID: 36822053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The accuracy of MRI in detecting pathological complete response following neoadjuvant chemotherapy in different breast cancer subtypes.
    Kuzmova M; Cullinane C; Rutherford C; McCartan D; Rothwell J; Evoy D; Geraghty J; Prichard RS
    Surg Oncol; 2023 Dec; 51():102011. PubMed ID: 37931546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy.
    Zarotti C; Papassotiropoulos B; Elfgen C; Dedes K; Vorburger D; Pestalozzi B; Trojan A; Varga Z
    Sci Rep; 2022 Jan; 12(1):91. PubMed ID: 34997055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
    Liu L; Li XR; Hu YH; Zhang J
    Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(12):940-3. PubMed ID: 27045718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
    Li JJ; Yu Y; Ge J
    Breast Cancer; 2023 May; 30(3):364-378. PubMed ID: 36656510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2-positive is an independent indicator for predicting pathological complete response to neoadjuvant therapy and Ki67-changed after neoadjuvant chemotherapy predicts favorable prognosis in Chinese women with locally advanced breast cancer.
    Fang Y; Zhang Q; Wu Y; Wu J
    Medicine (Baltimore); 2024 Feb; 103(6):e37170. PubMed ID: 38335419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy efficacy and prognosis in HER2-low and HER2-zero breast cancer patients by HR status: a retrospective study in China.
    Zhao S; Wang Y; Zhou A; Liu X; Zhang Y; Zhang J
    PeerJ; 2024; 12():e17492. PubMed ID: 38827304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.